The primary goal of this Mucosal Biology Scientific Research Support Component (SRSC) is to identify antibody effector functions at mucosal surfaces required to prevent HIV-1 acquisition, define how they differ by route of transmission, and through integrated studies across SRSCs (Mucosal, Vector, Non-human Primate) determine modes of protective antibody induction in non-human primates and in collaborative human clinical vaccine studies.
Specific Aims Aim 1. To support CHAVI-ID by defining the functional nature of protective antibody responses at mucosal surfaces elicited in RV144 follow-on trials (RV306, RV328), in other HlV-1 vaccine trials (HVTN 204, 082, 076) and in the HVTN/CHAVI501 mosaic trial.
Aim 2. To support CHAVI-ID by assessing the functional characteristics of protective antibodies at mucosal surfaces in NHP Core studies designed to determine optimal route/adjuvant combinations for the induction of mucosal immunity.
Aim 3. To support CHAVI-ID by evaluating the functional characteristics of protective antibodies at mucosal surfaces in NHP and Vector SRSC studies designed to determine optimal vector strategies for the induction of mucosal immunity.
Aim 4. To support CHAVI-ID by determining the impact of dimeric vs monomeric antibodies on mucosal acquisition.
The primary goal of this project is to identify the most effective components of vaccine induced responses at mucosal surfaces (vagina, rectum and penis) required to prevent HIV infection and to develop vaccine strategies that will induce and maintain such responses for a prolonged period (years).
|Song, Hongshuo; Giorgi, Elena E; Ganusov, Vitaly V et al. (2018) Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. Nat Commun 9:1928|
|Hurwitz, Julia L; Bonsignori, Mattia (2018) Multi-Envelope HIV-1 Vaccine Development: Two Targeted Immune Pathways, One Desired Protective Outcome. Viral Immunol 31:124-132|
|Yates, Nicole L; deCamp, Allan C; Korber, Bette T et al. (2018) HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. J Virol 92:|
|Castillo-Menendez, Luis R; Nguyen, Hanh T; Sodroski, Joseph (2018) Conformational Differences Between Functional Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Trimers and Stabilized Soluble Trimers. J Virol :|
|Finney, Joel; Kelsoe, Garnett (2018) Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design. Retrovirology 15:53|
|Bradley, Todd; Peppa, Dimitra; Pedroza-Pacheco, Isabela et al. (2018) RAB11FIP5 Expression and Altered Natural Killer Cell Function Are Associated with Induction of HIV Broadly Neutralizing Antibody Responses. Cell 175:387-399.e17|
|Richard, Jonathan; Prévost, Jérémie; Baxter, Amy E et al. (2018) Uninfected Bystander Cells Impact the Measurement of HIV-Specific Antibody-Dependent Cellular Cytotoxicity Responses. MBio 9:|
|Pardi, Norbert; Hogan, Michael J; Porter, Frederick W et al. (2018) mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov 17:261-279|
|Bowder, Dane; Hollingsead, Haley; Durst, Kate et al. (2018) Contribution of the gp120 V3 loop to envelope glycoprotein trimer stability in primate immunodeficiency viruses. Virology 521:158-168|
|Madani, Navid; Princiotto, Amy M; Mach, Linh et al. (2018) A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge. Nat Commun 9:2363|
Showing the most recent 10 out of 261 publications